Company Performance Metrics
Alastair Riddell: ChairmanPast Role: Feedback, Chairman
Gi Mikawa: CMO
Nemesis Bioscience is a UK-based biopharmaceutical company developing products to resurrect anti-microbial therapies made ineffective by increasing microbial resistance. The company develops Nemesis Symbiotics that will make existing antibiotics work again, prevent the spread of resistance genes, and so also protect the efficacy of new antibiotics.
The technology is applicable to all antibiotic classes, all known resistance mechanisms and all bacteria.
Other applications include reduction of chemotherapeutic toxicity, inactivation of virulence factors, and in vivo synthesis of biofuels and therapeutics.
The company was awarded the King’s College, Cambridge Entrepreneurship Award for 2014 and has filed patent applications internationally on its inventions.
